Prolonged remission of SAPHO syndrome with low‑dose leflunomide: A case report and literature review

This case report and literature review describes a 60-year-old woman from Southern Italy, diagnosed with synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome in 2015, who achieved sust ained remission through leflunomide therapy. Initially, the patient presented with severe sternoclavicular pain, osteitis and palmoplantar pustulosis. Following leflunomide initiation, the patient experienced significant clinical improvement, maintaining remission for ~5 years, even after a dose reduction to 20 mg on alternate days. No adverse events were reported during the entire treatment period. This case is contextualized within a concise review of the literature on leflunomide use in SAPHO, highlighting its potential as a long-term, low-dose therapeutic option with a favorable safety profile.

Authors

Institutions

Publication Details

Journal
Experimental and Therapeutic Medicine
Published
2025-12-05
DOI
https://doi.org/10.3892/etm.2025.13041
Primary Topic
Osteomyelitis and Bone Disorders Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prolonged remission of SAPHO syndrome with low‑dose leflunomide: A case report and literature review

Angelo Nigro
Experimental and Therapeutic Medicine
Osteomyelitis and Bone Disorders Research
article

Prolonged remission of SAPHO syndrome with low‑dose leflunomide: A case report and literature review

Angelo Nigro
article en

Abstract

This case report and literature review describes a 60-year-old woman from Southern Italy, diagnosed with synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome in 2015, who achieved sust ained remission through leflunomide therapy. Initially, the patient presented with severe sternoclavicular pain, osteitis and palmoplantar pustulosis. Following leflunomide initiation, the patient experienced significant clinical improvement, maintaining remission for ~5 years, even after a dose reduction to 20 mg on alternate days. No adverse events were reported during the entire treatment period. This case is contextualized within a concise review of the literature on leflunomide use in SAPHO, highlighting its potential as a long-term, low-dose therapeutic option with a favorable safety profile.

Experimental and Therapeutic MedicineVol. 31(2)
Ospedale Madonna Delle Grazie (IT)
Openalex Percentile: Top 45%
Osteomyelitis and Bone Disorders Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.